LUMIFY Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596600 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(5 years from now) | |
| US11833245 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(5 years from now) | |
| US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(6 years from now) | |
| US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(6 years from now) | |
Lumify is owned by Bausch And Lomb Inc.
Lumify contains Brimonidine Tartrate.
Lumify has a total of 4 drug patents out of which 0 drug patents have expired.
Lumify was authorised for market use on 22 December, 2017.
Lumify is available in solution/drops;ophthalmic dosage forms.
Lumify can be used as relieves redness of the eye due to minor eye irritations.
The generics of Lumify are possible to be released after 14 July, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2020 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of LUMIFY before it's drug patent expiration?
More Information on Dosage
LUMIFY family patents
